Psychedelics rewire brain activity, offering hope for mental health breakthroughs
Scientists have captured detailed images of brain activity in animals under the influence of psychedelics. The findings reveal how these substances alter perception and may explain their potential in treating mental health conditions. Until now, the exact mechanisms behind their effects on consciousness have remained unclear.
Psychedelics work by binding strongly to the serotonin 2A receptor. This interaction reduces the brain's ability to process external visual information. As a result, visual areas begin producing stronger low-frequency oscillations, particularly around 5 Hz.
These oscillations then drive activity in memory-related regions, such as the retrosplenial cortex. With less access to real-time sensory input, the brain starts filling gaps using stored memories. This shift explains why hallucinations occur—the mind relies more on internal imagery than external reality.
Researchers suggest this altered state could help break rigid negative thought patterns. In clinical settings, psychedelics like psilocybin have already shown promise. A Johns Hopkins study found that over 80% of cancer patients with treatment-resistant depression experienced lasting symptom relief after guided sessions. Similarly, COMPASS Pathways is testing a synthetic psilocybin formulation (COMP360) for severe depression, while early studies explore mescaline's potential for anxiety and mood disorders.
The study provides a clearer picture of how psychedelics reshape brain function. By understanding these mechanisms, clinicians may refine therapies for depression and anxiety. Further research could lead to more targeted treatments under medical supervision.
